Quentin S. Blackford net worth and biography

Quentin Blackford Biography and Net Worth

COO of DexCom

Quentin assumed the role of Chief Operating Officer in October 2019. In this role, he is responsible for Dexcom’s global operations, strategic development, and strategic growth. He also served as our Chief Financial Officer from September 2017 to March 2021.

Prior to Dexcom, Quentin served as NuVasive’s Executive Vice President, Chief Financial Officer, Head of Strategy and Corporate Integrity, where he played a key role in navigating the company through phases of significant growth and profitability improvements since 2009. He was instrumental in several acquisitions to build upon NuVasive’s portfolio of products and entry into new product segments, as well as geographic expansion. Prior to his roles at NuVasive, Mr. Blackford worked at Zimmer Holdings, Inc. where he led the organization’s Global Financial Planning & Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division.

Quentin has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Axogen, Inc. since May 2019.

Quentin is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.

What is Quentin S. Blackford's net worth?: The estimated net worth of Quentin S. Blackford is at least $11.94 million as of November 4th, 2024. Mr. Blackford owns 159,929 shares of DexCom stock worth more than $11,943,498 as of November 14th. This net worth evaluation does not reflect any other investments that Mr. Blackford may own. Learn More about Quentin S. Blackford's net worth.
How do I contact Quentin S. Blackford?: The corporate mailing address for Mr. Blackford and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Quentin S. Blackford's contact information.
Has Quentin S. Blackford been buying or selling shares of DexCom?: Quentin S. Blackford has not been actively trading shares of DexCom in the last ninety days. Learn More on Quentin S. Blackford's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Quentin S. Blackford Insider Trading History at DexCom

Quentin S. Blackford Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.68

$71.75

$75.78

50 Day Range

MA: $69.77

$65.68

$74.85

2 Week Range

Now: $74.68

$62.34

$142.00

Volume

4,192,267 shs

Average Volume

3,919,698 shs

Market Capitalization

$29.17 billion

P/E Ratio

44.72

Dividend Yield

N/A

Beta

1.17

Central Bank Abandons USD

From True Gold Republic | Ad

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.